Published in Obstet Gynecol on April 01, 2009
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | NCT00002540
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol (2015) 5.37
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 3.99
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med (2009) 2.29
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer (2010) 1.54
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst (2011) 1.39
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol (2012) 1.34
Laparoscopic optical coherence tomography imaging of human ovarian cancer. Gynecol Oncol (2009) 1.32
Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol (2011) 1.24
Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer (2013) 1.21
Biomarkers in the age of omics: time for a systems biology approach. OMICS (2011) 1.13
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer (2014) 1.10
Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol (2009) 1.10
Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol (2012) 1.05
Ovarian cancer: diagnosis and treatment. Dtsch Arztebl Int (2011) 1.05
In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem (2014) 1.04
Characteristic odour in the blood reveals ovarian carcinoma. BMC Cancer (2010) 1.03
E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer (2010) 1.02
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett (2010) 1.01
Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol (2010) 1.01
Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res (2011) 0.98
AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol Lett (2012) 0.96
Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther (2013) 0.96
Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Gynecol Oncol (2010) 0.92
Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet Gynecol (2013) 0.92
Identification of ovarian cancer symptoms in health insurance claims data. J Womens Health (Larchmt) (2010) 0.91
Ovarian cancer: to screen or not to screen. Obstet Gynecol (2009) 0.91
Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. Gynecol Oncol (2011) 0.88
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol (2016) 0.88
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2012) 0.87
CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem (2010) 0.87
Adnexal masses suspected to be benign treated with laparoscopy. JSLS (2012) 0.87
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila) (2012) 0.86
Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol (2010) 0.85
Designing early detection programs for ovarian cancer. Ann Oncol (2011) 0.85
Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PLoS One (2011) 0.84
Transvaginal ultrasonography in ovarian cancer screening: current perspectives. Int J Womens Health (2013) 0.84
Oophorectomy: the debate between ovarian conservation and elective oophorectomy. Menopause (2013) 0.84
Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. J Cancer Res Clin Oncol (2013) 0.83
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Mol Cancer Ther (2014) 0.83
Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis. J Natl Cancer Inst (2014) 0.83
Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS One (2015) 0.82
Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin Proteomics (2012) 0.81
Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer. PLoS One (2012) 0.80
IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. J Ovarian Res (2012) 0.77
Accuracy of ovarian and colon cancer risk assessments by U.S. physicians. J Gen Intern Med (2014) 0.77
Computer disease simulation models: integrating evidence for health policy. Acad Radiol (2011) 0.77
The Effect of Gynecologic Oncologist Availability on Ovarian Cancer Mortality. World J Obstet Gynecol (2014) 0.77
Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg (2010) 0.76
Ovarian cancer risk reduction through opportunistic salpingectomy. J Gynecol Oncol (2015) 0.76
Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. Biomed Res Int (2015) 0.75
Chinese Obstetrics & Gynecology journal club: a randomised controlled trial. BMJ Open (2016) 0.75
Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res (2017) 0.75
Use of Biomarkers in Screening for Cancer. EJIFCC (2010) 0.75
Update in women's health for the general internist. J Gen Intern Med (2010) 0.75
Complications from Surgeries Related to Ovarian Cancer Screening. Diagnostics (Basel) (2017) 0.75
Management of relapsed ovarian cancer: a review. Springerplus (2016) 0.75
14-3-3ζ Overexpression is Associated with Poor Prognosis in Ovarian Cancer. Yonsei Med J (2018) 0.75
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol (2000) 3.86
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol (2005) 3.15
Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol (2003) 2.58
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol (1992) 2.43
Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ (1996) 2.19
A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer (2007) 2.07
Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer (2000) 1.46
Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol (1997) 1.35
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr (2013) 6.18
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Long-term mortality after screening for colorectal cancer. N Engl J Med (2013) 5.81
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr (2005) 4.92
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med (2014) 4.76
Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. JAMA (2012) 4.71
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med (2011) 4.47
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med (2008) 4.22
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med (2008) 3.94
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA (2003) 3.82
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Utilization of surveillance colonoscopy in community practice. Gastroenterology (2009) 3.33
Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA (2013) 3.30
Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis (2009) 3.26
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med (2015) 2.88
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70